Department of Radiation Oncology, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Support Care Cancer. 2021 Jan;29(1):499-507. doi: 10.1007/s00520-020-05500-2. Epub 2020 May 13.
To evaluate the implementation of a cervix cancer-specific patient-reported outcome measure, the European Organization for Research and Treatment of Cancer Quality of Life Cervical Cancer module (EORTC QLQ-CX24), into gynecologic oncology clinics.
This was a prospective, multi-institutional, cross-sectional study involving cervix cancer patients previously treated with curative intent radiotherapy who were attending routine follow-up appointments. Between January 2017 and August 2018, eligible patients were approached to complete the EORTC QLQ-CX24 prior to their clinical encounter and then review it with their oncologist. Patient and oncologist experience was evaluated using Feedback Questionnaires following the encounter. Descriptive statistics were used to summarize the results of the EORTC QLQ-CX24 and Feedback Questionnaires. Open-ended questions within the Feedback Questionnaires were analyzed to identify themes.
Eighty-four patients consented to participate in the study. Of these, 80 (95.2%) completed the EORTC QLQ-CX24 and 76 (90.4%) completed both the EORTC QLQ-CX24 and the Feedback Questionnaires. There were high rates of completion for most items within the EORTC QLQ-CX24 (93-98%), except for items pertaining to vaginal symptoms and sexual health (34-35%). All eligible oncologists participated (n = 9). Overall, patients and oncologists positively endorsed use of the questionnaire during clinical encounters. The majority of patients (80%) and oncologists (89%) reported use of the questionnaire improved communication, including discussion of sensitive topics. Interestingly, only a minority of patients and oncologists stated a perceived preference for electronic completion (18% and 44%, respectively).
Implementation of the EORTC QLQ-CX24 in gynecologic oncology clinics was feasible and acceptable according to patients and oncologists.
评估宫颈癌特异性患者报告结局测量工具，欧洲癌症研究与治疗组织生活质量宫颈癌模块（EORTC QLQ-CX24），在妇科肿瘤学临床中的实施情况。
这是一项前瞻性、多机构、横断面研究，涉及先前接受根治性放疗治疗的宫颈癌患者，他们正在接受常规随访。在 2017 年 1 月至 2018 年 8 月期间，符合条件的患者在就诊前被邀请完成 EORTC QLQ-CX24，并与他们的肿瘤医生一起审查。在就诊后，使用反馈问卷评估患者和肿瘤医生的体验。使用描述性统计来总结 EORTC QLQ-CX24 和反馈问卷的结果。在反馈问卷中，对开放式问题进行分析，以确定主题。
84 名患者同意参与研究。其中，80 名（95.2%）完成了 EORTC QLQ-CX24，76 名（90.4%）完成了 EORTC QLQ-CX24 和反馈问卷。EORTC QLQ-CX24 的大多数项目（93-98%）的完成率较高，除了与阴道症状和性健康相关的项目（34-35%）。所有符合条件的肿瘤医生都参与了（n=9）。总体而言，患者和肿瘤医生都积极认可在临床就诊期间使用问卷。大多数患者（80%）和肿瘤医生（89%）表示使用问卷改善了沟通，包括讨论敏感话题。有趣的是，只有少数患者（18%）和肿瘤医生（44%）表示偏好电子填写。
根据患者和肿瘤医生的反馈，EORTC QLQ-CX24 在妇科肿瘤学临床中的实施是可行且可接受的。
